Monitor for interim Phase 1 data in the coming months, which could de-risk the TNX-1900 program and potentially catalyze investor interest. The use of LSCI as a biomarker may enhance credibility of results.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced the first participant dosed in a Phase 1 investigator-initiated study evaluating TNX-1900 (intranasal potentiated oxytocin) for craniofacial pain conditions, including migraine. The study, led by Dr. Antoinette Maassen van den Brink at Erasmus University, will assess the drug's effect on trigeminal neurovascular reactivity using Laser Speckle Contrast Imaging. This marks a proof-of-concept step for TNX-1900, which targets a pathway distinct from existing CGRP inhibitors.
Key Facts
- First participant dosed in a Phase 1 study of TNX-1900 for craniofacial pain, including migraine.
- Study evaluates TNX-1900's effect on trigeminal nerve-mediated vasodilation using capsaicin and electrical stimulation in healthy female volunteers.
- Principal investigator is Dr. Antoinette Maassen van den Brink at Erasmus University Medical Center.
- Uses Laser Speckle Contrast Imaging (LSCI) for real-time, high-resolution blood flow measurement.
- TNX-1900 targets oxytocin receptors in the trigeminal ganglion to block CGRP release, a mechanism distinct from CGRP receptor antagonists or antibodies.
- TNX-1900 is a drug-device combination with intranasal delivery to minimize systemic exposure.
Financial Impact
No financial figures disclosed; early-stage trial with no immediate revenue impact.
Risk Factors
- Early-stage development: Phase 1 data may not translate to clinical efficacy.
- Competition from established CGRP inhibitors and triptans with proven efficacy.
- No guarantee that targeting oxytocin receptors will effectively block migraine in humans.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262853 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.36 (−6.40%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.36 (−16.46%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.36 (+33.54%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.36 (−49.36%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.36 (−59.25%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.36 (−57.40%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.36 (−57.40%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.36 (−49.74%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.36 (−48.28%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.36 (−54.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers